A fatal case of EBV-associated lymphoproliferative disorder arising after a CD34-selected autologous peripheral blood stem cell transplant is reported in a patient with multiple myeloma in first plateau phase. It is suggested that this is likely to be a consequence of the accessory cell depletion associated with the CD34 ؉ cell purification and it is recommended that a source of autologous T cells is stored before transplantation to be used if a severe opportunistic infection or EBV lymphoma arises post-transplantation.
The use of peripheral blood stem cells (PBSC) following high-dose therapy has largely replaced the use of autologous bone marrow because of the more rapid haematological recovery that occurs 1, 2 and the attendant cost savings. 3 Initial pioneers of PBSC transplantation hoped that tumour contamination would be less with this source of stem cells 4 but it is clear that tumour contamination of the PBSC collection does occur. 5, 6 The use of CD34 ϩ cell purification of PBSC harvests has therefore become commonplace as a purging procedure. [6] [7] [8] CD34 ϩ cell purification is also used in attempted gene transfer procedures 9 and as a means of graft-versus-host disease prevention in the allogeneic setting. 10 We report here a case of EBV lymphoproliferative disorder following the use of an autologous purified CD34 ϩ cell transplant in a patient with multiple myeloma.
Case history
A 52-year-old female was diagnosed as having IgG kappa myeloma 6 months prior to high-dose therapy. presented with back pain and MRI scanning demonstrated a 6 cm epidural mass causing T2 to T4 spinal cord compression. She received 2000 cGy in five fractions to an 8 ϫ 12 cm field encompassing T2 to T8. Subsequent systemic therapy with five courses of cVAMP were completed with a reduction in her paraprotein from 50 g/l to 10 g/l. It was then elected to proceed to high-dose therapy with autologous CD34-purified peripheral blood stem cell (PBSC) transplantation in first plateau phase.
PBSCs were mobilized using cyclophosphamide 1.5 g/m 2 and G-CSF (filgrastim) 10 g/kg/day from the day after the administration of the cyclophosphamide until the completion of PBSC harvesting. Cells were collected on a continuous flow cell separator (Baxter CS3000; Baxter Healthcare, Northampton, UK) on three occasions (days [10] [11] [12] . The second and third apheresis products were subject to CD34 ϩ cell purification using a CEPRATE SC immunoaffinity column (CellPro, Bothell, WA, USA).
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The total CD34 dose in the purified cell fraction was High-dose therapy was given using melphalan and total body irradiation (TBI). Melphalan was given in a dose of 140 mg/m 2 on day Ϫ6 and TBI was given in a total dose of 10 Gy in five fractions on days Ϫ4 to Ϫ2. The day of stem cell return was designated day 0. She subsequently underwent a relatively uncomplicated immediate transplant recovery, her only problems being some mucositis, diarrhoea and fever (no organisms were cultured). By day 10 she regenerated a neutrophil count Ͼ0.5 ϫ 10 9 /l and she was independent of platelet transfusions from day 9. Symptoms of an upper respiratory tract infection delayed her discharge slightly but she was able to be discharged home on day 16 .
Over the next month she gradually became increasingly dyspnoeic on exertion, as well as suffering a dry cough. On day 51 she was readmitted to her local hospital due to the development of fever and rigors. Plain chest X-ray demonstrated intersitial ground glass shadowing and empirical Septrin therapy for pneumocystis pneumonia was instigated. She showed an initial improvement and was discharged from hospital 3 days later on continuing therapy.
By day 63 her symptoms had again worsened and she was treated, empirically, with ceftazidime and then erythromycin as well as amphotericin 1 mg/kg/day for 6 days. Despite this she suffered continuing swinging fevers and worsening dyspnoea. By day 73 she had become hypoxic (with oxygen saturations on air of 80%) and so she was transferred back to University College Hospital for further investigation. Bronchoscopy and bronchioalveolar lavage were performed but the procedure was poorly tolerated and transbronchial biopsy was not possible. Microscopy revealed a few gram-positive cocci but no definitive diagnostic information was obtained. In particular, there was no evidence of acid fast bacilli or pneumocystis. Open lung biopsy was considered but was not possible as her rapid pulmonary deterioration continued. Supportive therapy was continued for 3 days until her death on day 80.
Results of post-mortem examination
Both lungs were heavy and turgid with confluent petechiae over the pleural surfaces. Palpation of the lung showed a general lumpiness and upon slicing there were poorly defined pale infiltrates, predominantly close to the pleural surfaces. Histology showed a widely disseminated lymphoproliferative process characterised by diffuse infiltrates of transformed neoplastic appearing B lymphocytes. These included numerous bizarre multinucleated cells containing LMP1 protein, indicating a diagnosis of an EBV lymphoproliferative disorder. Attempts to ascertain the clonality of the tumour were unsuccessful due to poor quality DNA. It is of interest to note that anti-EBV lgG titres retrospectively performed on sample just prior to the transplant and just before death were unchanged at 1:64.
Discussion
High-dose chemo/radiotherapy with autologous haemopoietic stem cell transplantation may be of value in a number of clinical situations 12, 13 including multiple myeloma. 14 It has the advantage compared to allogeneic transplantation of a much lower procedure-related morbidity and mortality, but the disadvantage of the absence of an allogeneic graftversus-tumour effect, and the possibility of tumour contamination of the infused stem cells. In a condition such as multiple myeloma, for instance, high-dose therapy is typically given when disease is still detectable in the bone marrow by simple morphology. Contamination of the PBSC harvest is usually also detectable 6, 15 and, although at a lower level on a percentage cell basis, this is compounded by the fact that a greater number of cells are usually infused with a PBSC transplant than with a bone marrow transplant. Considerable attention has therefore been focused on methods of tumour eradication, ie purging. There is no direct evidence from randomised trials that purging reduces relapse rates, but there is evidence that tumour contamination of the graft can contribute to relapse. 16 Monoclonal antibodies reactive with differentiation or stage-specific antigens were initially developed for elimination of tumour cells (negative selection) using either complement lysis or immuno-physical separation techniques, 17, 18 but the processes were not commercialised to any extent. In 1984 Civin and colleagues 19 developed antibodies to the CD34 antigen whose expression was limited in the haemopoietic system to primitive cells including colony-forming cells and stem cells capable of long-term reconstitution. 7, 20 This led to the development of purging systems based on the positive selection of progenitor/stem cell populations expressing the CD34 antigen. 7, 8 Providing the tumour cells did not express this antigen, the single system could be used for purging in multiple diseases, a fact that lent itself to commercial development.
Such positive selection also removes T cells and other potential accessory cells. In a series of 10 CD34
ϩ immunopurification procedures using the CEPRATE system an average T cell depletion of greater than 3 logs was observed. 21 With some other systems even greater T cell depletion may occur. 21, 22 Removal of T cells from the graft does not result in delayed haemopoietic recovery 11, 21 when compared to unmanipulated grafts containing a similar number of CD34 ϩ cells, but could result in delayed immunological reconstitution. Malphettes and colleagues 23 reported that none of 12 patients with multiple myeloma receiving high-dose therapy with purified CD34 ϩ cell support had recovered to a normal CD4 ϩ lymphocyte count within 1 year of transplantation. This is in marked contrast to results with unmanipulated bone marrow 24, 25 or peripheral blood stem cell harvests. 25, 26 Brugger et al 27 noted an apparent increase in viral infections after CD34 ϩ -purified PBSC transplants and Nachbaur and colleagues 28 reported two cases of cryptosporidiosis after CD34-selected autologous PBSC transplants, infections that are rare in the autologous stem cell transplant setting but common in immunodeficiency states characterised by low CD4 ϩ cell counts. Another potential complication of impaired T cell function is the development of EBV-associated lymphoproliferative disorders. In the early stages they may be polyclonal, oligoclonal, or monoclonal, although the clonal nature of the proliferation does not appear to predict well for the aggressiveness of their behaviour. These lymphoproliferations occur particularly in the context of T cell-depleted allogeneic stem cell transplants where post-transplant immunosuppression is also given. 29 They have been rare in the autologous transplant setting and we are unaware of previous reports. We have not previously diagnosed such a case in our institution in over 1300 autologous stem cell procedures. Although there must always be doubts arising from single case reports it seems probable that the use of a purified CD34 ϩ cell product was implicated in this case. The patient had certainly not been very heavily pretreated compared to other autograft recipients. Awareness of the possibility of EBV-associated lymphomas is very important as they are exquisitely sensitive to adoptive donor T cell immunotherapy in the allogeneic setting, 30 and this patient would probably have responded to the infusion of the stored unmanipulated, T cell-replete PBSC harvest, had the diagnosis been made before death.
We suggest that back-up unmanipulated stem cells, or pre-mobilization T cells, are stored whenever a purified CD34 ϩ cell transplant is performed, ready for reinfusion in case of a severe opportunistic infection or EBV-associated lymphoproliferative disorder.
